Mitsubishi UFJ Financial Group
8306
Toyota Motor
7203
Mitsubishi
8058
4
Nintendo
7974
5
Nippon Telegraph & Telephone
9432
JP Stock MarketDetailed Quotes
4883 Modalis Therapeutics
- 78
- -1-1.27%
20min DelayMarket Closed Apr 4 15:30 JST
5.74BMarket Cap-1.01P/E (Static)
79High73Low3.58MVolume76Open79Pre Close271.27MTurnover20352wk High5.40%Turnover Ratio73.55MShares6252wk Low-64.98EPS TTM5.17BFloat Cap4070Historical HighLossP/E (Static)66.30MShs Float62Historical Low-77.24EPS LYR7.60%Amplitude--Dividend TTM4.86P/B100Lot Size--Div YieldTTM
About Modalis Therapeutics Company
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
Company Profile
Symbol4883
Company NameModalis Therapeutics
Founded2016-01-14
MarketTSE Growth
Employees37
Fiscal Year Ends12-31
Address16-5 Nihombashi-Kabuto-cho Chuo-ku
Zip Code103-0023
Phone03-6822-4584
Websitemodalistx.com
Company Executives
- Name
- Position
- Salary
- Haruhiko Morita
- Representative Director and President
- --
- Toshio Furuta
- Independent Director
- --
- Teruhisa Tashima
- Independent Director
- --
- Miyuki Shimane
- Independent Director
- --
- Joseph McCracken
- Independent Director
- --
- Hideki Takeda
- Independent Director
- --